

Special Issue

New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies

Message from the Guest Editors

It is our pleasure to announce a call for submissions to this Special Issue of *Cancers*, entitled "New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies". We welcome original research articles and reviews that cover any relevant topics in this area. Possible topics include, but are not limited to, the following:

- Role of the immune system in blood cancer progression and relapse, and advances in immunotherapies.
- Mechanisms of resistance and targeted therapies.
- Genomic and epigenetic mechanisms influencing clinical outcome, including mutations, gene fusions, copy number variations, and other chromosomal rearrangements.
- Exploiting metabolic vulnerabilities for personalised therapies, including mutations in key metabolic enzymes.
- Side effects and toxicities of the current blood cancer therapies, and strategies for reducing them.
- Omics approaches, including single-cell technologies, for identifying new biomarkers.
- RAS pathway mutations in blood cancers and new targeted therapies.
- Tumour microenvironment, cell dormancy, and relapse.

Guest Editors

Dr. Ilaria Stefania Pagani

Dr. Hannah Wardill

Dr. Teresa Sadras

Deadline for manuscript submissions

closed (31 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/120470

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)